PDE 5 INHIBITION: VIAGRA™ AND BEYOND

17/07/2012 - Room M203 at 14:00 - External Seminar
Andrew Bell
(Ex-Research Fellow Pfizer, currently at Imperial College)
Viagra™ (sildenafil) is a unique example of a chemical tool being used to discover the linkage between a biological mechanism and a disease through clinical trials. The presentation will describe the discovery of sildenafil and its use in defining the role of cGMP phosphodiesterases (particularly PDE5) in human diseases such as Male Erectile Dysfunction (MED) and Pulmonary Arterial Hypertension (PAH). These clinical studies, combined with the discovery of additional PDE isoforms, were used to define a desirable profile for subsequent 2nd generation PDE5 inhibitors. The impact of structural biology and high throughput screening on the discovery of further clinical candidates will also be discussed.
Hosted by: John Overington
Note: [Changed room]